FDA's traditional approval for Imdelltra followed 2024 accelerated nod
Records show Amgen's tarlatamab-dlle first won accelerated approval on May 16, 2024, before gaining traditional approval in November 2025.
FDA (2)
29 stories
Records show Amgen's tarlatamab-dlle first won accelerated approval on May 16, 2024, before gaining traditional approval in November 2025.
FDA (2)
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)
The FDA's own posting records accelerated approval for fam-trastuzumab deruxtecan-nxki for adults with unresectable or metastatic HER2-positive solid tumors.
FDA, Drugs@FDA (3)
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)
The agency's June 14, 2024 approval covers Amgen's Blincyto for patients as young as one month with CD19-positive, Philadelphia chromosome-negative disease.
FDA
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The commercial-stage dermatology company added the former AbbVie chief medical officer effective October 23, 2026, expanding its board to eleven members.
SEC filing
Gibbs joins Amgen's Audit and Compensation and Management Development committees effective immediately, expanding the board to 13 directors.
SEC filing
The company priced an 11.34 million ADS private placement at $22.04 per share and released a corporate presentation with fresh DLL3 ADC trial results.
SEC filing
FDA's drug database shows a second original BLA approval for Pavblu, with the agency's approval letter dated October 23, 2026.
Drugs@FDA
Former Sanofi CEO Hudson and Verily Health CFO Koppikar join as independent directors effective October 19, 2026, with board committee assignments and equity grants detailed in the filing.
SEC filing
The PAH drug developer added a cardiologist with Amgen and Kailera ties to its board as it advances a Phase 3 trial of IKT-001.
SEC filing
Farrow, who serves as CFO and chief strategy officer of Tarsus Pharmaceuticals, joins Lisata's Audit Committee as the board expands to eight members.
SEC filing
The FDA approved supplement 47 for Amgen's cholesterol drug Repatha on October 9, 2026, according to agency records.
Drugs@FDA
The single-site study, sponsored by MD Anderson with Amgen as collaborator, was suspended at the principal investigator's request, per a clinicaltrials.gov update posted October 8, 2026.
ClinicalTrials.gov
Hamill, who led Gilead's worldwide commercial operations, joins Entera's board effective December 1, 2026, replacing departing director Yonatan Malca.
SEC filing